key: cord-0266500-6hnhcwwk
authors: Brennan-Krohn, Thea; Friar, Liam; Ditelberg, Sarah; Kirby, James E.
title: Synergistic Activity of Minocycline and Rifampin in Combination with Antifungal Drugs against Candida auris
date: 2021-02-24
journal: bioRxiv
DOI: 10.1101/2021.02.23.432620
sha: d2c4c31d68f956b5f9891633282c433ef58aa1e8
doc_id: 266500
cord_uid: 6hnhcwwk

Candida auris is an emerging multidrug-resistant fungal pathogen that spreads readily in healthcare settings and has caused numerous hospital outbreaks. Very few treatment options exist for C. auris infections. We evaluated the activity of all two-drug combinations of three antifungal agents (amphotericin B, caspofungin, and voriconazole) and two antibacterial agents (minocycline and rifampin) against a collection of 10 C. auris isolates using an automated, inkjet printer-assisted checkerboard array method. Three antibacterial-antifungal combinations (amphotericin B plus rifampin, amphotericin B plus minocycline, and caspofungin plus minocycline) demonstrated synergistic activity by checkerboard array against ≥90% of strains. The two amphotericin B-containing combinations were also synergistic using the time-kill synergy testing method. Our results suggest that combinations of antifungal and antibacterial agents may provide a promising avenue for treatment of this multidrug-resistant pathogen.

The pathogenic yeast Candida auris, first identified in the external ear canal drainage of 29 a woman in Japan in 2009 (1), was classified by the U.S. Centers for Disease Control and 30

Prevention as one of the most urgent antibiotic resistance threats in 2019 (2). At least 4 distinct 31 clades of the yeast appear to have emerged nearly simultaneously on 3 different continents 32 around the time the first isolate was recognized (3). More recently, invasive C. auris infections 33 have been observed as a complication of critical SARS-CoV-2 disease (4-6). C. auris is most 34 commonly reported as a cause of bloodstream infections; patients with central venous 35 catheters and recent surgical procedures appear to be at particularly high risk (7). Compared to 36

other Candida species, C. auris is notable for its propensity to spread rapidly within healthcare 37 settings, for a high rate of mortality in infected patients, and for frequent resistance to multiple 38 antifungal drugs (8, 9) . 39

The number of drugs available to treat even the most susceptible of fungal pathogens is 40 small, with only three classes of systemic antifungal agents in general use: azoles, 41 echinocandins, and the polyene amphotericin B (AMB) (10) . Individual patient factors, such as 42 allergies, vulnerabilities to side effects, drug-drug interactions, and the need for penetration 43 into specific tissue sites frequently further constrain the choice of agents that can be safely and 44 effectively used; resistance to any of these agents may reduce practical treatment options to 45 few or none. In this context, the resistance profiles observed among C. auris isolates are 46 particularly alarming: nearly all isolates are resistant to fluconazole, and some also demonstrate 47 resistance to echinocandins and AMB (7, 11). Isolates resistant to drugs from all three classes 48 have been reported (12) . 49

Unfortunately, the antifungal drug pipeline is unlikely to yield an abundance of new 50 treatment options in the near future. Antifungal drug development is hampered by intrinsic 51 challenges (fungi, like humans, are eukaryotic organisms, and therefore it is difficult to identify 52 compounds that are active against fungal pathogens but not highly toxic to host cells) and by 53 poor financial incentives for pharmaceutical companies (10) . Ibrexafungerp, a first-in-class 54 glucan synthase inhibitor, has recently been shown to have activity against C. auris (13) in in 55 vitro and animal models (14), but has not yet been approved for clinical use. 56

One treatment approach that does not rely on the introduction of novel agents is the 57 repurposing of existing drugs in combination. Combination therapy using two or more 58 antifungal drugs is already an established component of therapy for certain fungal infections: 59 AMB is routinely used in combination with 5-fluorocytosine as induction therapy for 60

Cryptococcus neoformans meningitis (15), while combinations of antifungal drugs are often 61 employed in an attempt to treat infections caused by highly drug-resistant molds such as 62 7 considered synergistic and/or fungicidal if at least one of these combinations met criteria for 116 synergistic or fungicidal activity, respectively. At 24 hours, AMB plus RIF and AMB plus MIN 117 were synergistic against all 5 strains, while at 48 hours, AMB plus RIF was synergistic against 4 118 strains and AMB plus MIN against 3 strains. In combination with RIF, AMB showed fungicidal 119 activity against 2 strains at 24 and 48 hours, and against an additional strain at 24 hours, at 120 concentrations at which it was not fungicidal alone. In combination with MIN, AMB showed 121 fungicidal activity against 2 strains at 24 and 48 hours at concentrations at which it was not 122 fungicidal alone. The combination of CAS plus MIN was not synergistic or fungicidal against any 123 strains. The synergy killing curves for this combination were notable in that CAS exhibited an 124 inhibitory or near-inhibitory effect even at concentrations at or below the BMD MIC, yet its We identified three combinations of antibacterial and antifungal drugs (AMB plus RIF, 132 AMB plus MIN, and CAS plus MIN) that demonstrated synergistic activity by checkerboard array 133 against ≥90% of C. auris strains evaluated; the two AMB-containing combinations were also 134 synergistic by time-kill synergy testing at one or more concentration combinations against the 135 strains evaluated. We thereby demonstrate synergistic activity between antibacterial and 136 antifungal agents against the emerging and highly multidrug-resistant pathogen C. auris. 137 8 We hypothesize that the mechanism of synergy for these combinations involves 138 impairment in cell wall or membrane integrity by the antifungal drug, permitting entry of an 139 antibacterial agent that would otherwise be unable to access the intracellular compartment of 140 a fungal cell. Echinocandins such as CAS act by inhibiting b-(1,3)-glucan synthase, thus impeding 141 cell wall synthesis and impairing cell wall integrity, resulting in increased vulnerability of the cell 142 to osmotic pressure (27). AMB has traditionally been understood to act by forming ion channels 143 in the lipid bilayer of the fungal cell membrane, thus permeabilizing the cell and ultimately 144 causing cell death (28, 29). However, recent work suggests that large aggregates of AMB, which 145 assemble outside the membrane and act as "sterol sponges" that kill cells by extracting 146 ergosterol from the lipid bilayer, may play a more important role in cell death than do the ion 147 channels (30). It is conceivable that at the subinhibitory concentrations at which it 148 demonstrates synergy with MIN and RIF, AMB could be exerting ion channel permeabilizing 149 activity without aggregate-based cytotoxicity, allowing entry of the antibacterial drugs through 150 the channels. 151

Our hypothesis is supported by prior observations that tetracycline inhibits protein 152 synthesis in isolated yeast ribosomes (31) and that RIF appears to inhibit RNA polymerase in 153 yeast (17). These drugs, therefore, may have targets in yeast cells analogous to those in 154 bacteria but accessible in yeast only in the setting of disruption of cell membrane or cell wall 155 integrity. A similar phenomenon is well established in bacteria, whereby drugs that are unable 156 to bypass the defenses of the Gram-negative outer membrane under normal circumstances 157 demonstrate activity in the presence of low levels of membrane-permeabilizing agents such as 158 polymyxins (32, 33). 159 9 We used two separate synergy testing methods in an effort to increase the robustness 160 of our results, and found that while two combinations demonstrated consistent synergy using 161 both methods, a third was synergistic only by the checkerboard array method and not the time-162 kill method. It is possible that this finding reflects a limitation of the synergistic activity of this 163 combination (CAS plus MIN). Alternatively, the finding may reflect the limitations of the time-164 kill testing method for evaluation of CAS activity, as our single-drug CAS killing curves did not 165 demonstrate concentration-dependent inhibitory or fungicidal effects, a finding that has been 166 previously observed with this drug in C. auris (26). 167

In this study we also demonstrated the utility of an automated inkjet printer-assisted 168 digital dispensing method for MIC and checkerboard array synergy testing in yeast. Manual 169 synergy testing is an error-prone and time-consuming process, and automation allows for 170 significantly higher throughput of the technique, thereby facilitating more rapid investigation of 171 novel combinations. This use of the DDM for MIC and synergy testing of bacteria, first described 172 in our laboratory (34, 35), has been adopted by the United States Centers for Disease Control 173 and Prevention to test drug combinations against multidrug-resistant bacterial pathogens (36) 174 and has the potential for similar use for fungal pathogens such as C. auris. 175

In vitro synergy testing has certain intrinsic limitations and is not always a direct 176 indicator of in vivo efficacy (37). However, identification of combinations with in vitro activity 177 provides preliminary data to suggest regimens that may ultimately prove to be of therapeutic 178 benefit. Given the paucity of new antifungal drugs in the development pipeline, regimens that 179 involve readily available drugs for which extensive pharmacokinetic and safety data already 

Antibiotic resistance threats in the United States. U.S. Department of Health and 304 Human Services

Multidrug-resistant candida auris infections in 308 critically Ill Coronavirus disease patients

Candida auris : 310 A Latent Threat to Critically Ill Patients With Coronavirus Disease

Simultaneous emergence of multidrug-317 resistant candida auris on 3 continents confirmed by whole-genome sequencing and 318 epidemiological analyses

Candida auris: an Emerging Fungal Pathogen

Candida auris: A review of the literature

Antifungal drugs: the current armamentarium and 324 development of new agents

Comparison of EUCAST and 326 CLSI reference microdilution mics of eight antifungal compounds for candida auris and associated 327 tentative epidemiological cutoff values

Candida auris Isolates Resistant to Three Classes of Antifungal Medications -331

SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison 334 with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents

Efficacy of 337 ibrexafungerp (SCY-078) against candida auris in an in vivo guinea pig cutaneous infection model

Combination Antifungal Therapy for Cryptococcal 342 Meningitis

345 Infections caused by Scedosporium spp

Potentiation of rifampicin